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CONCLUSION 
  We confirm that analysing a single region of the genome to extrapolate the HCV genotype leads to misidentification of HCV 
recombinant forms 
 The misidentification of these forms leads to treatment failure. In the case presented here the additional cost of the 
treatment, follow-up and laboratory analysis was estimated above 70 000 euros  
 We urgently need rapid and easy methods for the whole genome sequencing of HCV to avoid such costly consequences 
 All suspicions of recombinant strains  can be investigated by the method described herein 
The use of new Direct Acting Antivirals (DAA) specific of Hepatitis C 
Virus (HCV), has greatly improved the virological suppression, and for 
the most recent ones, the biological and clinical tolerance of HCV 
treatment. Most of the DAA do not haveyet  a pangenotypic action, 
which means that most of them have a predominant action on specific 
HCV genotype. This observation led to different recommendations in 
the treatment of HCV genotype 1, 2, 3, and 4 infections.  
Genotyping methods may target different regions of the HCV 
genome, although only the whole genome sequencing could confirm 
the correct genotype. We report the case of a patient, infected with an 
unusual recombinant 2k/1b recombinant HCV form which was falsely 
diagnosed with an HCV genotype 2 infection, and treated with an 
unadapted treatment, leading to a treatment failure.  
INTRODUCTION PATIENT 
In 2005, a 42-year-old Ukrainian male, was diagnosed with an HCV 
infection, which was genotyped as a genotype 2 using the Genekit HCV 
5’NC (Visible). In May 2014, he started a 12 week treatment with 
sofosbuvir (400 mg daily) and ribavirin (600 mg twice daily), following 
our national guidelines for genotype 2 treatment. The pre-treatment 
HCV RNA plasma viral load (pVL) was 5.7 log UI/mL. Four weeks after, 
the pVL was <12 UI/mL and remained undetectable until the end of 
treatment in August 2014. Two weeks after, the pVL was detectable, 
and rose to 6.1 log UI/mL eight weeks after the end of the treatment. 
After this virological failure, a retreatment was decided in July 2015 
with the same drug association but for 24 weeks. In the meantime, we 
decided to check the genotype using a previously described method 
targeting the NS5B region. 
• Both 5’ Core and 3’ NS5B region of the genome were sequenced to 
confirm the presence of a putative recombinant virus 
• A cDNA covering the region from E1 to NS3 was synthesised, and 
sequenced by the Sanger method with a set of 15 primers adapted 
from previously published methods 
• Bioinformatic analysis was performed by NCBI Genotyping, BLAST, 
Neighbour Joining phylogenetic analysis and SimPlot sequences 
METHODS 
Regions targeted for genotyping assay 
Proteins targeted by HCV  
direct acting antivirals 
Region amplified to  determine 
the recombination breakpoint 
RESULTS 
• Sequencing of the Core region at the beginning of the genome 
confirmed the phylogenetic proximity to genotype 2k HCV 
 
• Sequencing of the NS5B region at the end of the genome confirmed 
the phylogenetic proximity to genotype 1b HCV 
 
• Comparison of the NS5B gene to HCV 1a and 1b reference strains, 
and recombinant 2k/1b described in Russia and Cyprus made us 
focus the region from E1 to NS3 to search for the recombination 
breakpoint, as the breakpoint is usually situated in this part of the 
genome in these circulating strains 
 
 
 
 
 
 
 
 
 
 
• Similarity of the complete sequence of 1699 nucleotides, from E1 to 
NS3,  was compared to different genotype query sequences to 
identify the recombination breakpoint using SimPlot software 
• SimPlot analysis showed a recombination breakpoint at the final 
part of the NS2 gene as described below 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Similarity plot of the 2k/1b E1 to NS3 
HCV region  
Plot was generated by the SimPlot 
software with 200 nucleotides (nt) 
windows, 20 nt increments, and the 
Kimura 2-parameter method with a 
transition-transversion (Ts/Tv) ratio of 2.0. 
The sample was queried against 3 
different 2k/1b HCV recombinants in red, 
green and yellow, a genotype 1b 
reference strain in blue, and a genotype 
2k reference strain in grey [HQ537005 
(2k1b), AY587845 (2k1b), HQ537006 
(2k1b), AB031663 (2k), AB016785 (1b)]. 
